Overview
VivoSense builds digital endpoints from wearable sensor data to support clinical trials. It designs, collects, cleans, analyzes, and reports trial data, often through a proprietary cloud platform that clients access under service contracts. It differentiates itself by turning wearable data into validated, auditable biomarkers and offering an integrated end-to-end workflow from design to reporting. Its goal is to improve the precision and efficiency of clinical trials, enabling real-time monitoring and faster paths to treatments.
Work here?Claim your company
Simplify's take
What believers are saying
- October 2026 hiring for test and marketing roles signals active product and commercial expansion.
- The July 2026 DiMe sponsorship broadens VivoSense’s visibility across the digital endpoints ecosystem.
- A 2022 $25 million Series A still supports algorithm development and trial execution capacity.
What critics are saying
- No digital endpoint has won primary drug-approval status by June 2026.
- Wearables stay underutilized in pharma trials, limiting demand and delaying budgets.
- If sponsors keep treating sensors as optional, VivoSense’s category never becomes standard practice.
What makes VivoSense unique
- Dudley Tabakin’s team built the wearable sensor CRO model by July 2026.
- VivoSense combines study design, operationalization, analytics, and regulatory evidence into one workflow.
- Its 2010 clinical-research focus gives depth in digital endpoints competitors still lack.
Help us improve and share your feedback! Did you find this helpful?